E
EyePoint, Inc (EYPT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$0.31
+0.00 (+0.52%)
Market Cap: $34.82M
Last updated: Nov 17, 2026 at 11:05 AM ET
EyePoint, Inc (EYPT) Valuation Multiples
EyePoint (EYPT) trades at 10.6x sales and 0.3x book value. Its P/S of 10.6x is above its 5-year median of 9.4x. Its forward P/E is 6.2x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 6.2x |
| Price to sales | 10.6x |
| Price to book | 0.3x |
| EV/FCF | 0.2x |
| PEG | N/A |
| FCF yield | -1089.7% |
Historical Medians
Against its 10-year medians, its P/S is 10.4% above 9.6x and its P/B is 93.8% below 4.8x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 10.6x | 9.4x | 9.6x |
| P/B | 0.3x | 2.7x | 4.8x |
Valuation History
Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 1.3x in 2020 to 40.8x in 2025. 2025 was the highest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $18.27 | 40.8x | 5.0x |
| 2024 | $7.45 | 9.7x | 1.4x |
| 2023 | $23.11 | 19.6x | 3.7x |
| 2022 | $3.50 | 3.2x | 1.4x |
| 2021 | $12.24 | 9.6x | 2.2x |
| 2020 | $6.58 | 1.3x | 5.1x |
| 2019 | $15.50 | 8.0x | 19.9x |
| 2018 | $18.90 | N/A | 4.8x |
| 2017 | $10.80 | 16.4x | 4.9x |
| 2016 | $17.10 | 38.7x | 39.6x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About EYPT
What is EYPT's forward P/E ratio?
EyePoint has a forward P/E ratio of 6.2x.
Is EYPT stock overvalued?
GNG's valuation label for EYPT is Undervalued.
What is EYPT's price to sales ratio?
EyePoint has a price to sales ratio of 10.6x.
EYPT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors